Table 6

Sensitivity analyses of NashTest for the diagnosis of Nash versus No Nash or Borderline Nash [Area under the ROC curves (AUROCs)], according to group, ALT values, alcohol consumption, quality of biopsy, inclusion of patients without steatosis, and exclusion of high risk of biomarkers failures.

Characteristic of patients

n

NashTest AUROC

Lower 95%

Upper 95%

Prevalence NASH

Significance between AUROCs


All 257 patients

257

0.75

0.67

0.82

0.25

Stratified according to Group*

Training Group

160

0.79

0.69

0.86

0.18

0.94

Validation Group

97

0.79

0.67

0.87

0.36

Stratified according to ALT value*

ALT < 50 IU/L

92

0.78

0.58

0.89

0.17

0.58

ALT >= 50 IU/L

165

0.73

0.64

0.81

0.28

Stratified according to Alcohol consumption*

None

95

0.72

0.57

0.82

0.31

0.78 and 0.28

< 30 g for men and < 20 g for female

150

0.77

0.66

0.84

0.19

0.78 and 0.33

>= 30 g for men or >= 20 g for female

12

0.94

0.53

0.99

0.50

0.28 and 0.33

Quality of biopsy*

< 25 mm

194

0.76

0.66

0.83

0.25

0.72

>= 25 mm

63

0.73

0.55

0.84

0.24

Fragmented

148

0.71

0.58

0.80

0.22

0.15

Not Fragmented

109

0.81

0.70

0.88

0.28

Patients included or excluded

Patients without steatosis included**

277

0.76

0.68

0.82

0.39

0.85

High risk of NashTest failures excluded**

Gilbert excluded

244

0.76

0.68

0.82

0.25

0.78

Acute Inflammation excluded

254

0.75

0.67

0.82

0.24

0.95


* Comparison between stratified groups

** Comparison with all 257 patients

Poynard et al. BMC Gastroenterology 2006 6:34   doi:10.1186/1471-230X-6-34

Open Data